We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · May 19, 2022

Cannabis and Cannabinoids for Symptomatic Treatment in People With MS

The Cochrane Database of Systematic Reviews


Additional Info

Disclosure statements are available on the authors' profiles:

The Cochrane Database of Systematic Reviews
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Cochrane Database Syst Rev 2022 May 05;5(2022)CD013444, G Filippini, S Minozzi, F Borrelli, M Cinquini, K Dwan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading